TD Cowen analyst Dan Brennan initiated coverage of Alamar Biosciences (ALMR) with a Buy rating and $30 price target The company’s Nulisa chemistry and “easy-to-use, robust” Argo platform offer a one-two combination that is generating material enthusiasm at pharma and proteomics customers, the analyst tells investors in a research note. The firm believes Alamar’s ales are set to more than double from 2025 to 2027 and grow at 40% annually through 2030.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMR: